Baidu
map

ASCO 2020:低免疫毒副作用的PD-L1抗体令人叹服

2020-05-30 MedSci MedSci原创

相比于化疗,免疫治疗药物的副作用较小,但部分患者还是会发生免疫性肠炎/肺炎等副作用,甚至还会发生致死性心脏炎。因此,低免疫毒性的新型免疫治疗药物备受期待。

相比于化疗,免疫治疗药物的副作用较小,但部分患者还是会发生免疫性肠炎/肺炎等副作用,甚至还会发生致死性心脏炎。因此,低免疫毒性的新型免疫治疗药物备受期待。

CX-072是CytomX Therapeutics公司开发的一种靶向PD-L1的Probody疗法,目前处于I/II期临床。Probody是一类完全重组的单克隆抗体,其抗原结合位点利用专利性的抗体掩蔽技术进行封闭,在健康组织中保持惰性,而在肿瘤微环境中能被肿瘤特异的蛋白酶切割从而被选择性激活,暴露出抗原结合位点。跟一般PD-1/PD-L1抗体不同,CX-072抗体在设计的时候加了一把“锁”,正常组织没有开锁的钥匙,只有肿瘤组织才能把“锁”解开。所以,CX-072在正常组织中无效,保持了PD-L1分子的正常功能,副作用降低。

Probody聚焦于治疗性抗体对肿瘤的活性,同时对健康组织无害。Probody独特的选择性,扩展了已验证及新颖靶标的治疗窗口,有望创造更安全有效的新一类疗法。

CX-072的新型PD-L1抗体的一项研究引起了大家的关注,80多位患者无一例发生严重免疫性肺炎和肠炎,具体数据请参考下图。

同时,初步的临床数据显示,CX-072针对小细胞肺癌、三阴乳腺癌还有不错的疗效,值得期待。

目前,CytomX公司有4个Probody项目处于临床开发,包括该公司独家拥有的PD-L1 Probody免疫疗法(CX-072)、与百时美施贵宝合作开发的一款CTLA-4靶向性Probody疗法(BMS-986249)、独家拥有的CD166靶向性Probody药物偶联物(CX-2009)、与艾伯维合作开发的一款CD71靶向性Probody药物偶联物(CX-2029)。
ROCLAIM-CX-072-002是一项开放标签、多中心II期研究(NCT03993379),在接受一种PD-1/PD-L1免疫检查点抑制剂治疗后病情进展或复发的不可切除性或转移性黑色素瘤患者中开展,将评估CX-072与Yervoy免疫组合疗法的疗效、安全性和耐受性。

2019年CytomX Therapeutics公司宣布启动II期PROCLAIM(人体Probody临床评估)CX-072-002研究,评估抗PD-L1 Probody CX-072联合百时美施贵宝抗CTLA-4抗体Yervoy(ipilimumab,易普利姆玛)治疗复发性或难治性黑色素瘤患者。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2078797, encodeId=59a420e87971a, content=<a href='/topic/show?id=6dbc635680d' target=_blank style='color:#2F92EE;'>#毒副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63568, encryptionId=6dbc635680d, topicName=毒副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Feb 11 11:24:21 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939069, encodeId=26251939069e7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Feb 19 10:24:21 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824348, encodeId=c90318243483c, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Dec 13 16:24:21 CST 2020, time=2020-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255067, encodeId=7fff125506e94, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Jun 01 13:24:21 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344236, encodeId=263513442362e, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2830, encryptionId=7649283021, topicName=ASCO 2020)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Jun 01 13:24:21 CST 2020, time=2020-06-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2078797, encodeId=59a420e87971a, content=<a href='/topic/show?id=6dbc635680d' target=_blank style='color:#2F92EE;'>#毒副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63568, encryptionId=6dbc635680d, topicName=毒副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Feb 11 11:24:21 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939069, encodeId=26251939069e7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Feb 19 10:24:21 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824348, encodeId=c90318243483c, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Dec 13 16:24:21 CST 2020, time=2020-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255067, encodeId=7fff125506e94, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Jun 01 13:24:21 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344236, encodeId=263513442362e, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2830, encryptionId=7649283021, topicName=ASCO 2020)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Jun 01 13:24:21 CST 2020, time=2020-06-01, status=1, ipAttribution=)]
    2021-02-19 quxin068
  3. [GetPortalCommentsPageByObjectIdResponse(id=2078797, encodeId=59a420e87971a, content=<a href='/topic/show?id=6dbc635680d' target=_blank style='color:#2F92EE;'>#毒副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63568, encryptionId=6dbc635680d, topicName=毒副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Feb 11 11:24:21 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939069, encodeId=26251939069e7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Feb 19 10:24:21 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824348, encodeId=c90318243483c, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Dec 13 16:24:21 CST 2020, time=2020-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255067, encodeId=7fff125506e94, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Jun 01 13:24:21 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344236, encodeId=263513442362e, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2830, encryptionId=7649283021, topicName=ASCO 2020)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Jun 01 13:24:21 CST 2020, time=2020-06-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2078797, encodeId=59a420e87971a, content=<a href='/topic/show?id=6dbc635680d' target=_blank style='color:#2F92EE;'>#毒副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63568, encryptionId=6dbc635680d, topicName=毒副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Feb 11 11:24:21 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939069, encodeId=26251939069e7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Feb 19 10:24:21 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824348, encodeId=c90318243483c, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Dec 13 16:24:21 CST 2020, time=2020-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255067, encodeId=7fff125506e94, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Jun 01 13:24:21 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344236, encodeId=263513442362e, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2830, encryptionId=7649283021, topicName=ASCO 2020)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Jun 01 13:24:21 CST 2020, time=2020-06-01, status=1, ipAttribution=)]
    2020-06-01 smartjoy
  5. [GetPortalCommentsPageByObjectIdResponse(id=2078797, encodeId=59a420e87971a, content=<a href='/topic/show?id=6dbc635680d' target=_blank style='color:#2F92EE;'>#毒副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63568, encryptionId=6dbc635680d, topicName=毒副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Feb 11 11:24:21 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939069, encodeId=26251939069e7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Feb 19 10:24:21 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824348, encodeId=c90318243483c, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Dec 13 16:24:21 CST 2020, time=2020-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255067, encodeId=7fff125506e94, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Jun 01 13:24:21 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344236, encodeId=263513442362e, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2830, encryptionId=7649283021, topicName=ASCO 2020)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Jun 01 13:24:21 CST 2020, time=2020-06-01, status=1, ipAttribution=)]

相关资讯

J Gastroenterology:PD-L1表达对原发性胃和肠弥漫性大B细胞淋巴瘤的预后影响

弥漫性大B细胞淋巴瘤(DLBCL)是一种最常见的胃肠道淋巴瘤。胃和肠道DLBCL(giDLBCL)患者的预后指标在其解剖部位之外存在争议。因此,本项研究旨在比较程序性细胞死亡配体1(PD-L1)表达在预测giDLBCL预后中的作用。

Lancet Oncol :Atezolizumab联合卡波铂和nab-paclitaxel用于非小细胞肺癌术前化疗

Atezolizumab联合卡波铂和nab-paclitaxel治疗可作为可切除非小细胞肺癌术前化疗的新辅助治疗方案,有很高比例的患者获得了病理反应

Brit J Cancer:PD-L2和PD-L1表达在食管癌患者中预后和临床意义

PD-L2和PD-L1与食管癌患者的不良预后相关,这支持了PD-L2作为食管癌预后生物标志物的作用。

总结:PD-L1免疫组化检测难点与要点

PD-L1(programmed death ligand 1)全称程序性死亡受体配体1,是PD-1(programmed cell death 1,程序性死亡受体1)的配体。PD-L1属于细胞膜上的

Chest:非小细胞肺癌支气管超声引导下经支气管针吸活检术检测PD-L1

EBUS-TBNA提供的样本足以进行PD-L1检测,并且晚期患者和存在脑转移与PD-L1表达升高相关。

不可切除III期非小细胞肺癌迎来免疫治疗新时代!PD-L1单抗在中国获批!

肺癌持续占据我国恶性肿瘤发病率和死亡率的首位,严重威胁着人们的健康。疫情当前,肺癌患者群体也面对着更为严峻的挑战。肺癌发病率和死亡率居高不下,是全社会共同面对的问题。肺癌的病期决定患者的预后,而准确的临床分期是制定肺癌治疗方案的重要依据。因此,在治疗前判断患者的分期,选择不同的治疗策略是肺癌诊疗的关键。2019年12月,中国国家药品监督管理局(NMPA)正式批准度伐利尤单抗注射液(商品名:英飞

Baidu
map
Baidu
map
Baidu
map